Download PDF
CC BY 4.0 · Indian J Med Paediatr Oncol
DOI: 10.1055/s-0045-1808062
Original Article

Undifferentiated/Dedifferentiated Carcinomas of the Endometrium: A Retrospective Clinicopathological Study of a Series of 11 Cases

Reshmi J.S 
1   Department of Pathology, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Kedar Deodhar
1   Department of Pathology, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Bharat Rekhi 
1   Department of Pathology, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Neha Mittal
1   Department of Pathology, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Rohini Kulkarni 
2   Department of Gynecologic Oncology, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Sneha Raj
2   Department of Gynecologic Oncology, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Biswajit Dash
2   Department of Gynecologic Oncology, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Sushmita Rath
3   Department of Medical Oncology, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Seema Gulia
3   Department of Medical Oncology, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Jaya Ghosh
3   Department of Medical Oncology, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Supriya Chopra
4   Department of Radiation Oncology, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Prachi Mittal 
4   Department of Radiation Oncology, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Amita Maheshwari
2   Department of Gynecologic Oncology, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Akshay Baheti 
5   Department of Radiodiagnosis, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Nilesh Sable
5   Department of Radiodiagnosis, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Sudeep Gupta
3   Department of Medical Oncology, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Santosh Menon 
1   Department of Pathology, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, Maharashtra, India
› Author Affiliations
Funding None.
› Further Information
Also available at
  Permissions and Reprints

Abstract

Introduction Undifferentiated endometrial carcinomas (UDECs) are rare subtypes of endometrial carcinomas with aggressive clinical behavior. Histologically, UDEC exhibits a solid growth pattern and consists of monomorphic, discohesive, small to medium-sized round cells, with absent to minimal neuroendocrine differentiation. When UDEC is accompanied by a differentiated carcinoma component (usually International Federation of Gynecology and Obstetrics [FIGO] grade 1 or 2), it is termed dedifferentiated endometrial carcinoma (DDEC). The diagnosis of these tumors is challenging because of their close histological similarity to grade 3 endometrioid adenocarcinomas.

Objectives This article aims to understand and elucidate the clinical presentation, pathological findings, treatment options, and outcomes of UDEC/DDEC.

Materials and Methods Diagnosed/suspected cases of UDEC/DDEC, based on pathology reports between January 2018 and January 2023, were retrieved from the pathology database. Clinical, treatment, and follow-up details were retrieved from the electronic medical record database.

Results Out of the 21 cases reviewed, 10 cases were reclassified as “grade 3 endometrioid adenocarcinoma” and 1 case as carcinosarcoma based on histomorphology and immunohistochemical findings. There were 11 cases of undifferentiated carcinoma, out of which 7 were reconfirmed and assigned a DDEC diagnosis. Lower uterine segment involvement was seen in 45% of cases. Out of the 11 patients, 6 patients were diagnosed with stage IIC disease, 4 patients with stage IIIC disease, and 1 patient with stage IV disease (FIGO 2023 staging). Mismatch repair (MMR) protein deficiency was seen in 50% of tested cases and loss of SMARCA4 (BRG1) was seen in one case. Four patients received adjuvant concurrent chemoradiation, one patient received adjuvant chemotherapy, and one patient received neoadjuvant chemotherapy. Six patients had no evidence of disease at follow-up ranging from 6 to 24 months. Two patients had disease progression and one patient died of disease.

Conclusion UDECs and DDECs are rare endometrial tumors that show characteristic histomorphology, weak/absent immunohistochemistry staining for EMA/PAX8, and MMR protein deficiency in a subset of cases. It is important to have a high index of suspicion for these tumors due to close mimickers, their aggressive behavior, and the potential role of treatment with immunotherapy.

Keywords

undifferentiated - dedifferentiated - endometrium - mismatch repair

Patient Consent

A waiver of consent was obtained from Institutional Ethics Committee.




Publication History

Article published online:
17 April 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Silva EG, Deavers MT, Malpica A. Undifferentiated carcinoma of the endometrium: a review. Pathology 2007; 39 (01) 134-138
    PubMedSearch in Google Scholar
  • 2 Matias-Guiu X, Longacre TA, McCluggage WG. et al. Tumors of the uterine corpus. In: Female Genital Tumours: WHO Classification of Tumours. 5th ed.. Lyon, France: International Agency for Research on Cancer; 2020
    Search in Google Scholar
  • 3 Murali R, Davidson B, Fadare O. et al. High-grade endometrial carcinomas: morphologic and immunohistochemical features, diagnostic challenges and recommendations. Int J Gynecol Pathol 2019; 38 (1, Suppl 1): S40-S63
    PubMedSearch in Google Scholar
  • 4 AlHilli M, Elson P, Rybicki L. et al. Undifferentiated endometrial carcinoma: a National Cancer Database analysis of prognostic factors and treatment outcomes. Int J Gynecol Cancer 2019; 29 (07) 1126-1133
    PubMedSearch in Google Scholar
  • 5 Ramalingam P, Masand RP, Euscher ED, Malpica A. Undifferentiated carcinoma of the endometrium: an expanded immunohistochemical analysis including PAX-8 and basal-like carcinoma surrogate markers. Int J Gynecol Pathol 2016; 35 (05) 410-418
    PubMedSearch in Google Scholar
  • 6 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
    CrossrefPubMedSearch in Google Scholar
  • 7 Tafe LJ, Garg K, Chew I, Tornos C, Soslow RA. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Mod Pathol 2010; 23 (06) 781-789
    PubMedSearch in Google Scholar
  • 8 Abeler VM, Kjørstad KE, Nesland JM. Undifferentiated carcinoma of the endometrium. A histopathologic and clinical study of 31 cases. Cancer 1991; 68 (01) 98-105
    PubMedSearch in Google Scholar
  • 9 Yokomizo R, Yamada K, Iida Y. et al. Dedifferentiated endometrial carcinoma: a report of three cases and review of the literature. Mol Clin Oncol 2017; 7 (06) 1008-1012
    PubMedSearch in Google Scholar
  • 10 Garg K, Shih K, Barakat R, Zhou Q, Iasonos A, Soslow RA. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset. Am J Surg Pathol 2009; 33 (12) 1869-1877
    PubMedSearch in Google Scholar
  • 11 Altrabulsi B, Malpica A, Deavers MT, Bodurka DC, Broaddus R, Silva EG. Undifferentiated carcinoma of the endometrium. Am J Surg Pathol 2005; 29 (10) 1316-1321
    PubMedSearch in Google Scholar
  • 12 Silva EG, Deavers MT, Bodurka DC, Malpica A. Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma?. Int J Gynecol Pathol 2006; 25 (01) 52-58
    PubMedSearch in Google Scholar
  • 13 Han J, Ki EY, Rha SE, Hur S, Lee A. Dedifferentiated endometrioid carcinoma of the uterus: report of four cases and review of literature. World J Surg Oncol 2017; 15 (01) 17
    PubMedSearch in Google Scholar
  • 14 Ferguson SE, Tornos C, Hummer A, Barakat RR, Soslow RA. Prognostic features of surgical stage I uterine carcinosarcoma. Am J Surg Pathol 2007; 31 (11) 1653-1661
    PubMedSearch in Google Scholar
  • 15 Li Z, Zhao C. Clinicopathologic and immunohistochemical characterization of dedifferentiated endometrioid adenocarcinoma. Appl Immunohistochem Mol Morphol 2016; 24 (08) 562-568
    PubMedSearch in Google Scholar
  • 16 Hoang LN, Lee YS, Karnezis AN. et al. Immunophenotypic features of dedifferentiated endometrial carcinoma: insights from BRG1/INI1-deficient tumours. Histopathology 2016; 69 (04) 560-569
    PubMedSearch in Google Scholar
  • 17 Castrillon DH, Lee KR, Nucci MR. Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study. Int J Gynecol Pathol 2002; 21 (01) 4-10
    PubMedSearch in Google Scholar
  • 18 Saad RS, Mashhour M, Noftech-Mozes S. et al. P16INK4a expression in undifferentiated carcinoma of the uterus does not exclude its endometrial origin. Int J Gynecol Pathol 2012; 31 (01) 57-65
    PubMedSearch in Google Scholar
  • 19 Kolin DL, Quick CM, Dong F. et al. SMARCA4-deficient uterine sarcoma and undifferentiated endometrial carcinoma are distinct clinicopathologic entities. Am J Surg Pathol 2020; 44 (02) 263-270
    PubMedSearch in Google Scholar
  • 20 McMeekin DS, Tritchler DL, Cohn DE. et al. Clinicopathologic significance of mismatch repair defects in endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol 2016; 34 (25) 3062-3068
    CrossrefPubMedSearch in Google Scholar
  • 21 Kihara A, Amano Y, Matsubara D, Fukushima N, Fujiwara H, Niki T. BRG1, INI1, and ARID1B deficiency in endometrial carcinoma. Am J Surg Pathol 2020; 44: 1712-1724
    PubMedSearch in Google Scholar
  • 22 Cancer C. NCCN Guidelines for Patients. Uterine Cancer.; 2024.
  • 23 Espinosa I, Lee CH, D'Angelo E, Palacios J, Prat J. Undifferentiated and dedifferentiated endometrial carcinomas with POLE exonuclease domain mutations have a favorable prognosis. Am J Surg Pathol 2017; 41 (08) 1121-1128
    PubMedSearch in Google Scholar
  • 24 Yamashita H, Nakayama K, Ishikawa M. et al. Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer. Oncotarget 2017; 9 (05) 5652-5664
    PubMedSearch in Google Scholar
  • 25 Makker V, Taylor MH, Aghajanian C. et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol 2020; 38 (26) 2981-2992
    CrossrefPubMedSearch in Google Scholar
  • 26 Azad NS, Gray RJ, Overman MJ. et al. Nivolumab is effective in mismatch repair-deficient noncolorectal cancers: results from arm Z1D-A subprotocol of the NCI-MATCH (EAY131) Study. J Clin Oncol 2020; 38 (03) 214-222
    Search in Google Scholar
  • 27 Stewart CJR, Crook ML. SWI/SNF complex deficiency and mismatch repair protein expression in undifferentiated and dedifferentiated endometrial carcinoma. Pathology 2015; 47 (05) 439-445
    PubMedSearch in Google Scholar
  • 28 Wang Y, Chen SY, Karnezis AN. et al. The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type. J Pathol 2017; 242 (03) 371-383
    PubMedSearch in Google Scholar
  • 29 Üreyen I, Ilgin H, Turan T. et al. Undifferentiated uterine carcinoma: analysis of eighteen cases. J Obstet Gynaecol 2015; 35 (04) 372-376
    PubMedSearch in Google Scholar